-
Mashup Score: 0
In the US, the incidence of pancreatic cancer is increasing in patients of all ages, and the incidence of colorectal cancer is increasing in patients aged 15-34 years.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
The most common projected cancers in adults were lung cancer, colon cancer, leukemia, bladder cancer, and stomach cancer.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet-
Radiation from computed tomography scans may cause as many as 5% of #cancers diagnosed each year in the United States. Published in @JAMAInternalMed. https://t.co/Hxw3L94EVt
-
-
Mashup Score: 0Childhood Cancer Survivors Have Higher Risk of Chronic Conditions, Early Death - Oncology Nurse Advisor - 1 day(s) ago
Childhood cancer survivors “may experience considerable accelerated aging throughout their lifespan,” the researchers wrote.
Source: www.oncologynurseadvisor.comCategories: General Medicine NewsTweet-
#Childhoodcancer survivors are more likely than the general population to develop chronic health conditions and die before reaching 65 years of age. Published in @JAMAOnc and @CancerTherAdvsr. https://t.co/mnZlg0AxRG #PedOnc
-
-
Mashup Score: 0
Using both liquid and tissue biopsies to guide targeted treatment may improve outcomes in patients with solid tumor malignancies.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet-
Using both liquid and tissue biopsies to guide targeted treatment may improve outcomes in patients with solid tumor malignancies, according to results from the ROME trial presented at #AACR25. https://t.co/8vRKMfAF1o
-
-
Mashup Score: 0Opinion: Chemo-Free Regimens Join Crowded Field of Potential Therapies for Osimertinib-Resistant NSCLC - 1 day(s) ago
Results from phase 2 trials appear to support the use of chemotherapy-free regimens in patients with osimertinib-resistant NSCLC.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet-
Results from phase 2 trials appear to support the use of chemotherapy-free regimens in pts with osimertinib-resistant NSCLC. Data presented at #ELCC25 by @LeXiuning of @MDAndersonNews, Dr Ross Soo of @NCIS_NUHS, Dr Myung-Ju Ahn, & @stephanieplsaw. #lcsm https://t.co/SIcLKACO2i
-
-
Mashup Score: 0
New research suggests that a ctDNA assay can detect colorectal cancer recurrence months before it is detected via imaging.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet-
New research suggests that a ctDNA assay can detect colorectal cancer recurrence months before it is detected via imaging. These findings were presented at #AACR25 by @emma_titmuss of @BCCancer. #crcsm #gicsm https://t.co/0zwfSRKvPq
-
-
Mashup Score: 0The Grand Roundup - 2 day(s) ago
We are introducing a new way to deliver the most relevant information you need for your patients on the topics that matter most to your clinical practice.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet-
Sign up today for our bi-weekly email covering emerging research, conference news, and guideline updates on general oncology, breast cancer and lung cancer: https://t.co/Yn7x746tB1 https://t.co/M8zAlDAuZQ
-
-
Mashup Score: 3
“These results may help guide management strategies and prognostication among patients with advanced NSCLC who experience severe irAE and in whom permanent ICI discontinuation is required,” the researchers wrote.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet-
New research suggests that several factors are associated with PFS and OS among patients with advanced #NSCLC who stop taking ICIs due to immune-related adverse events. Reported in @CCR_AACR. https://t.co/fHHeuqsn8k #lcsm
-
-
Mashup Score: 0
The estimated incidence of hypertension was highest among patients receiving ribociclib.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet-
The risk of cardiotoxicity may vary across CDK4/6 inhibitors, according to a study of patients with #breastcancer published in the @JNCCN. https://t.co/RgJEZTvzdl #bcsm
-
-
Mashup Score: 4Zongertinib Confers Benefit in HER2-Mutant NSCLC - 3 day(s) ago
Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet-
Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial. These results were presented at #AACR25 by Dr John Heymach of @MDAndersonNews. #lcsm https://t.co/2vmMc1qMe6
-
In the US, the incidence of pancreatic cancer is increasing in patients of all ages, and the incidence of colorectal cancer is increasing in patients aged 15-34 years. From @JAMANetworkOpen. https://t.co/biII1TwAgG #gicsm #pancsm #crcsm